

SHCP APC Summary

Date: May 2024

(Applications were approved virtually via FutureNHS platform)

The Link to previous SHCP APC minutes are available [HERE](#)

SHCP APC item	Virtually approved
Deflazacort Medicine Information sheet , for the treatment of Duchenne's Muscular Dystrophy (DMD) in people up to 19 years of age	Approved – the renewal of the information sheet Shared care - Sussex Health & Care (ics.nhs.uk)
Tyenne (Tocilizumab) formulary extension	Approved – the addition of tocilizumab biosimilar Tyenne to the formulary with a RED formulary coding for indications as per the originator.
NICE Technology Appraisals	
NICE TA878 Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19	For noting (updated NICE TA) , no further action.
NICE TA953 Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema	Approved RED formulary coding
NICE TA954 Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	Approved RED formulary coding
NICE TA956 Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over	Approved RED formulary coding
NICE TA957 Momelotinib for treating myelofibrosis-related splenomegaly or symptoms	Approved RED formulary coding
NICE TA958 Ritlecitinib for treating severe alopecia areata in people 12 years and over	Approved RED formulary coding
NICE TA959 Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis	Approved RED formulary coding
NICE TA962 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy	Approved RED formulary coding
NICE TA963 Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent	Approved RED formulary coding

endometrial cancer with high microsatellite instability or mismatch repair deficiency	
NICE TA964 Cabozantinib with nivolumab for untreated advanced renal cell carcinoma	Approved RED formulary coding
NICE Guidelines	
NG51 Suspected sepsis: recognition, diagnosis and early management	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
NG195 Neonatal infection: antibiotics for prevention and treatment	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
NG191 COVID-19 rapid guideline: managing COVID-19	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
NG239 Vitamin B12 deficiency in over 16s: diagnosis and management	The ICB Blood and Nutrition therapeutic Lead will propose a change and submit an application to the APC regarding the formulary status of oral cyanocobalamin.
New BlueTeq forms	
May 2024	
Fluocinolone – chronic diabetic macular oedema (TA953) – application form	
Discontinuations	
31 st May 2024	Insulatard InnoLet (insulin isophane human) 100units/ml suspension for injection 3ml pre-filled disposable devices
31 st May 2024	Levemir InnoLet (insulin detemir) 100units/ml solution for injection 3ml pre-filled disposable devices
January 2024	Fortisip Yoghurt style liquid
December 2023	Ensure plus yoghurt Style liquid
February 2024	Nutrison Soya 500ml
February 2024	Peptisorb 1000ml
1 st December 2024	Pabrinex (Vitamins B and C) Intramuscular High Potency Solution for injection ampoules
Not Specified	Calcipotriol 50micrograms/ml scalp solution
20 th March 2024	Klean-Prep oral powder 69g sachets sugar free
22 nd April 2024	Follitropin alfa 75unit powder and solvent for solution for injection ampoules
31 st May 2024	Daktacort 2%/1% cream
1 st April 2024	Asacol 400mg MR gastro-resistant tablets
Unknown	Nonoxilon-9 gel
1 st June 2024	GoResp Digihaler 160micrograms/dose / 4.5micrograms/dose dry powder inhaler (Teva UK Ltd)
1 st June 2024	GoResp Digihaler 320micrograms/dose / 9micrograms/dose dry powder inhaler (Teva UK Ltd)